Skip to content
    PRAX
    Earnings call· Mar 2026(Q1 FY26)

    Praxis Precision Medicines Q1 FY26 earnings call PRAX

    May 7, 2026 Source

    Executive summary

    Praxis Precision Medicines Q1 FY26 — Late-Stage Assets Progress, Commercial Ramp, and Pipeline Catalysts

    Praxis Precision Medicines is accelerating its transition to a commercial company, driven by significant progress across four late-stage assets with over $20 billion in peak sales potential. The company is actively preparing for two potential U.S. launches in the next eight months, supported by strong clinical data and a robust financial foundation. Key pipeline catalysts are expected throughout the year, including pivotal readouts and regulatory decisions, as Praxis aims to deliver life-altering treatments for CNS disorders.

    Highlights

    5

    • NDAs for ulixacaltamide and relutrigine accepted by FDA with PDUFA dates set for January 29, 2027, and September 27, 2026, respectively.

    • Recruitment completed for the EMBOLD study (relutrigine in broad DEE), with top-line results expected in Q4 2026.

    • Positive results from EMBRAVE Part A for easinersen in SCN2A early onset DEE, showing a 77% placebo-adjusted reduction in monthly seizures.

    • Strong cash, cash equivalents, and marketable securities balance of $1.4 billion as of March 31, 2026, expected to fund operations into 2028.

    • Ulixacaltamide profile validated by over 2,300 U.S. physicians and 1,300 ET patients, reinforcing its >$10 billion peak sales potential.

    Concerns

    2

    • Operating cash used was $86 million in Q1 FY26, an increase from $53 million in Q1 FY25, reflecting greater clinical trial activity and commercial preparations.

    • Competitive drugs in focal epilepsy have shown high discontinuation rates of 22% to 25% and dose reductions of 25% on the top dose, highlighting tolerability challenges in the class.

    Guidance & targets

    7
    CategoryTargetConfidence
    Ulixacaltamide PDUFA date
    January 29, 2027
    high materiality
    High
    Relutrigine PDUFA date
    September 27, 2026
    high materiality
    High
    EMBOLD study top-line results
    Q4 this year
    high materiality
    High
    POWER1 study readout
    later this quarter
    high materiality
    High
    POWER2 study completion
    this year
    medium materiality
    High
    POWER2 study readout
    early next year
    medium materiality
    High
    Cash runway
    into 2028
    high materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Ulixacaltamide (Essential Tremor)
    Validated ulixacaltamide profile across efficacy, breadth of benefits, and tolerability, reinforcing its potential.
    US physicians surveyed: >2,300ET patients surveyed: >1,300
    		————
    Relutrigine (SCN2A & 8A-DEE, broader DEE)
    Recruitment for the EMBOLD study in broad DEE completed in record time, with high interest from patients and investigators.
    EMBOLD study recruitment: Completed
    		————
    Vormatrigine (Focal Epilepsy)
    Most potent and selective sodium channel modulator developed for 3.5 million people living with epilepsy in the United States.
    POWER1 Phase III study: Readout later this quarterPOWER2 Phase III study: Completion by year-end, readout early next yearPOWER3 study: Initiation planned
    		————
    Elsunersen (SCN2A early onset DEE)
    Positive results from EMBRAVE Part A showed disease-modifying effect and substantial seizure reduction.
    EMBRAVE Part A enrollment: 9 children (aged 2 to 12)
    		————

    Operational metrics

    14
    Operating expenses
    $106 million
    Q1 FY26

    Driven by ramping activities and hiring related to commercial launch preparations.

    R&D expenses
    $78 million
    Q1 FY26
    SG&A expenses
    $28 million
    Q1 FY26
    Operating cash used
    $86 millionvs $53 million in Q1 FY25
    Q1 FY26

    Reflecting greater clinical trial activity, headcount growth, and commercial launch preparations.

    Cash, cash equivalents, and marketable securities
    $1.4 billionvs $926 million as of December 31, 2025
    as of March 31, 2026

    Increase primarily attributable to net proceeds from January 2026 follow-on public offering and interest income.

    Relutrigine broader DEE market expansion
    20-fold
    Future

    Expansion towards the DEE is like 20-fold what the initial indication for SCN2&8A is.

    Relutrigine broader DEE patient population
    >200,000
    US
    Essential Tremor US patient population
    7 million
    US
    Essential Tremor US patients in immediate need
    2 million
    US
    Essential Tremor US patients actively seeking treatment or recently treated
    2 million to 2.5 million
    US

    Either who are being treated and seeing a physician at this moment or just done it and are sitting on the sidelines.

    Vormatrigine US epilepsy patients
    3.5 million
    US
    Oral chronic therapy compliance and retention
    60% to 80%
    General

    General numbers for classical oral chronic therapy.

    Competitive drug discontinuation rate
    22% to 25%
    Recent competitive events

    Discontinuation rate for drugs people are excited about.

    Competitive drug dose reduction (top dose)
    25%
    Recent competitive events

    Dose reduction on the top dose for drugs people are excited about.

    Industry KPIs

    4
    MetricValueDetails
    Pipeline read out calendarMultiple readouts
    Regulatory approvals filings2 NDAs accepted
    Peak long term sales guidance>$10 billionUSD
    Clinical trial efficacy safety data77%%

    Risks & headwinds

    4
    Tolerability concerns for Ulixacaltamide in early treatment phaseShort-term (first few days/weeks of treatment)

    happens on the first few days and first few weeks

    Mitigation: Physicians are comfortable managing; company is providing guidance on patient management (e.g., calling patients, advising).

    Potential for competitive drugs to have high discontinuation rates and dose reductions due to tolerabilityOngoing

    22% to 25% discontinuation with a further 25% dose reduction on the top dose

    Mitigation: Vormatrigine's profile is competitive, with lower discontinuation rates observed.

    Stigma and lack of awareness for Essential Tremor leading to under-diagnosis/treatmentOngoing

    7 million patients have essential tremor, but only 2 million are in immediate need of a therapy

    Mitigation: 'Essential to Me' disease state campaign to bring awareness and encourage patients to seek treatment.

    Pricing policies in the United States impacting ex-US strategiesOngoing

    Not quantified

    Mitigation: Company is focusing on the U.S. market first and not splitting geographies with others.

    What to watch in Q2 FY26

    5

    Vormatrigine POWER1 Phase III readout

    Later this quarter (Q2 FY26)
    CurrentStudy ongoing
    TargetTop-line results

    Why it matters

    This is a key clinical catalyst for the focal epilepsy program, informing future development and commercial potential.

    We're also on track to report results from our POWER1 study for lamotrigine later this quarter.

    Q&A highlights

    7

    What data supports relutrigine's efficacy in broader DEE, and what gives confidence in EMBOLD study success?

    Marcio explained the scientific rationale based on sodium channel modulation, preclinical animal models, and FDA agreement. He highlighted the high level of interest from physicians and the significant commercial potential (20-fold expansion) for the broader DEE population, emphasizing the need to generate positive returns to invest in future therapies.

    “The expansion towards the DEE is like 20-fold what the initial indication for SCN2&8A is, which is incredibly important. But the second part makes not only scientific sense, but it's a tremendous upside in terms of the potential of this drug.”

    asked by Yasmeen Rahimi · answered by Marcio Souza

    2 min read6 chapters

    Detailed Narrative

    01

    Commercial Readiness for Ulixacaltamide

    Praxis is ramping up commercial efforts for Ulixacaltamide, with a PDUFA date of January 29, 2027. The commercial leadership team is in place, and plans are underway for field force hiring and training in advance of the launch. The company is expanding its commercial infrastructure across operations, marketing, access, and compliance, and has successfully established a distribution network to ensure drug availability upon potential approval.

    02

    Physician and Patient Validation for Ulixacaltamide

    An extensive observational study involving over 2,300 U.S. physicians and 1,300 ET patients validated Ulixacaltamide's profile across efficacy, breadth of benefits, and tolerability. These results reinforced the drug's potential for over $10 billion in peak sales and the significant unmet need in the market. The company also highlighted its robust presence at the American Academy of Neurology Annual Meeting, with 15 scientific presentations, including a plenary presentation on the Essential3 program results.

    03

    Relutrigine for DEE Programs

    The FDA has accepted relutrigine's NDA with priority review for seizures associated with SCN2A & 8A-DEE, setting a PDUFA date of September 27, 2026. Commercial preparations are advancing, including hiring, inventory building, patient support programs, and payer engagement. Additionally, recruitment for the EMBOLD study in the broader DEE population has been completed in record time, with top-line results expected in Q4 2026, which could significantly expand relutrigine's commercial potential.

    04

    Vormatrigine Program Updates

    Vormatrigine, described as the most potent and selective sodium channel modulator for epilepsy, has several key milestones approaching. The readout of the POWER1 Phase III study is expected later this quarter. The company plans to initiate the POWER3 study, a monotherapy trial, in the near future. Enrollment for the POWER2 Phase III study, which evaluates 20, 30, and 40 milligrams once daily, is progressing well, with completion expected by year-end and readout early next year.

    05

    Elsunersen (ASO Platform) Progress

    Praxis reported positive results from EMBRAVE Part A for easinersen, the first ASO on its platform, for SCN2A early onset DEE. The study, which enrolled 9 children, demonstrated a 77% placebo-adjusted reduction in monthly seizures and disease-modifying components across multiple domains, while maintaining a generally safe and well-tolerated profile. These results, combined with open-label extension data, underscore the drug's transformational potential.

    06

    Essential Tremor Market Dynamics and Awareness

    Of the 7 million Americans living with essential tremor, approximately 2 million are in immediate need of therapy. The gap between the prevalent population and those seeking treatment is attributed to the progressive nature of the disease, societal stigma, and a historical lack of effective treatments. Praxis has launched the 'Essential to Me' disease state campaign to raise awareness and encourage patients to seek treatment, aiming to change these dynamics.

    AI-generated summary of the company’s earnings call. Not investment advice.